share_log

AI/ML Innovations Inc. Chosen for Healthcare Micro Payment Integration Utilizing TodaQ MicroPay Technology

AI/ML Innovations Inc. Chosen for Healthcare Micro Payment Integration Utilizing TodaQ MicroPay Technology

AI/ML Innovations Inc.選擇利用TodaQ MicroPay技術進行醫療保健小額支付集成
Accesswire ·  04/10 20:30

VICTORIA, BC / ACCESSWIRE / April 10, 2024 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is proud to announce the launch of its innovative "Follow Your Heart" brand, featuring Micro Payment integration by TodaQ MicroPay. As part of this unique initiative, AI/ML's Follow Your Heart products have been selected as the first healthcare platform to leverage TodaQ MicroPay technology as the result of a successful Pilot Program, marking an important advancement in accessible healthcare solutions.

不列顛哥倫比亞省維多利亞州/ACCESSWIRE/2024年4月10日/致力於收購和推進滿足緊急社會需求的人工智能/機器學習技術的領先公司AI/ML Innovations Inc.(CSE: AIML)(OTCQB: AIML)(FWB: 42FB)自豪地宣佈推出其創新的 “Follow Your Heart” 品牌,該品牌由TodaQ MicroPay集成了小額支付。作爲這項獨特計劃的一部分,AI/ML的Follow Your Heart產品在試點計劃成功後被選爲第一個利用TodaQ MicroPay技術的醫療保健平台,這標誌着無障礙醫療解決方案取得了重要進展。

Empowering Health Through Micro Payments: The Follow Your Heart Brand

通過小額支付增強健康:Follow Your Heart 品牌

Follow Your Heart, powered by AI/ML's proprietary AI PrecisionPulse Neural Network, represents a new trend in cardiovascular health monitoring. With the tagline "Discover Wellness in Every Beat," Follow Your Heart embodies our commitment to empowering individuals to take control of their well-being. Now, with TodaQ MicroPay integration, Follow Your Heart can further empower its channel partners with micropayment and distribution capabilities for Blood Pressure estimates and other biometric data.

由人工智能/機器學習專有的人工智能 PrecisionPulse 神經網絡提供支持的 Follow Your Heart 代表了心血管健康監測的新趨勢。Follow Your Heart 的口號是 “在每一次跳動中發現健康”,體現了我們致力於讓個人能夠控制自己的健康的承諾。現在,通過集成TodaQ MicroPay,Follow Your Heart可以進一步爲其渠道合作伙伴提供小額支付和分發功能,用於血壓估算和其他生物識別數據。

Key Features of Follow Your Heart:

Follow Your Heart 的主要特點:

  • Utilizes AI/ML's advanced Neural Net for Blood Pressure measurement
  • Features EdgeAI and PrecisionPulse measurement technology for enhanced accuracy
  • Offers seamless integration with TodaQ MicroPay for micropayment and distribution
  • 利用 AI/ML 的高級神經網絡進行血壓測量
  • 採用 EdgeAI 和 PrecisionPulse 測量技術,可提高精度
  • 提供與 TodaQ MicroPay 的無縫集成,用於小額支付和分配

Expanding Access Through Retail Pharmacy and Beyond

通過零售藥房及其他渠道擴大准入

Follow Your Heart will be available for purchase through retail pharmacy channels and other outlets serving patients with hypertension. By making the product accessible through diverse channels, AI/ML aims to reach a wide audience and empower individuals to proactively manage their cardiovascular health.

Follow Your Heart 可通過零售藥房渠道和其他爲高血壓患者提供服務的門店購買。通過讓產品可通過多種渠道獲得,AI/ML 旨在覆蓋廣泛的受衆,使個人能夠主動管理自己的心血管健康。

Paul Duffy, CEO of AI/ML Innovations Inc. stated, "We are thrilled to introduce the Follow Your Heart brand and its integration with TodaQ MicroPay. This collaboration represents an innovative advancement in healthcare accessibility, allowing individuals to access essential health solutions seamlessly. Follow Your Heart embodies our commitment to innovation and empowerment, and we are excited to see the positive impact it will have on individuals' lives."

AI/ML Innovations Inc.首席執行官保羅·達菲表示:“我們很高興推出Follow Your Heart品牌及其與TodaQ MicroPay的整合。這種合作代表了醫療保健可及性方面的創新進步,使個人能夠無縫地獲得基本的健康解決方案。Follow Your Heart 體現了我們對創新和賦權的承諾,我們很高興看到它將對個人生活產生積極影響。”

Hassan Khan, CEO and Founder of TodaQ Micro added, "We are excited to partner with AI/ML Innovations Inc. with a whole new approach to healthcare payments through Micro Payment technology. TodaQ MicroPay's integration with Follow Your Heart underscores our shared commitment to making healthcare more accessible and convenient for everyone. Together, we are working to reshape the landscape of healthcare payments, one innovative partnership at a time."

TodaQ Micro首席執行官兼創始人哈桑·汗補充說:“我們很高興與AI/ML Innovations Inc.合作,通過小額支付技術提供一種全新的醫療支付方式。TodaQ MicroPay與Follow Your Heart的整合凸顯了我們共同的承諾,即讓每個人都能更容易獲得和便捷的醫療保健。我們正在共同努力重塑醫療支付格局,一次只能建立一種創新的合作伙伴關係。”

###

###

Explore AI/ML's "Follow Your Heart Product Page" here

在這裏瀏覽 AI/ML 的 “關注你的心臟產品頁面”

About AI/ML Innovations Inc.

關於 AI/ML Innovations Inc.

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

AI/ML Innovations Inc.調整了其業務運營,以利用新興的人工智能(AI)和機器學習(ML)領域,最初的投資重點是新興的數字健康和福祉公司,這些公司利用人工智能、機器學習、雲計算和數字平台推動變革性的醫療管理解決方案和整個健康連續體的精準支持交付。通過與Health Gauge(AIML持有95.2%的股權)、Tech2Heal(高達22%的所有權,目前由AIML持有12.44%的所有權)、AI Rx Inc.(AIML持有70%的股權)以及其他計劃中的增值投資,公司繼續利用不斷擴大的增長領域,使公司所有利益相關者受益。AI/ML的股票在加拿大證券交易所交易,代碼爲 “AIML”,OTCQB風險投資市場以 “AIMLF” 的形式交易,在法蘭克福證券交易所交易的代碼爲 “42FB”。

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

代表董事會
蒂姆·丹尼爾斯,執行主席

For more information about AI/ML Innovations:

有關 AI/ML 創新的更多信息:

For detailed information please see AI/ML's website or the Company's filed documents at

有關詳細信息,請訪問AI/ML的網站或公司提交的文件,網址爲

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com

欲了解更多信息,請致電 (778) 405-0882 或 info@aiml-innovations.com 與 Blake Fallis 聯繫

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CSE及其監管服務提供商(該術語在CSE的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

For AI/ML Innovations Investors

致人工智能/機器學習創新投資者

Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .

本新聞稿中發表的某些非基於歷史信息的陳述是前瞻性陳述,涉及大量已知和未知的風險和不確定性。本新聞稿包含與AI/ML Innovations對管理層計劃、目標和戰略(包括捍衛公司知識產權的戰略)的預期有關的明示或暗示的前瞻性陳述。這些陳述既不是承諾也不是擔保,但存在各種風險和不確定性,其中許多風險和不確定性是我們無法控制的,這可能導致實際結果與這些前瞻性陳述中設想的結果存在重大差異。提醒現有和潛在投資者不要過分依賴這些前瞻性陳述,這些陳述僅代表截至本文發佈之日。除非適用的證券法明確要求,否則AI/ML Innovations Inc. 沒有義務更新或修改本新聞稿中包含的信息,無論是由於新信息、未來事件或情況還是其他原因。有關不確定性和風險的更多信息,可以在AI/ML向證券監管機構提交的披露文件中找到,網址爲。

SOURCE: AI/ML Innovations Inc.

來源:AI/ML Innovations Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論